On the heels of the recent reintroduction of the PERA and PREVAIL Acts of 2025, a bipartisan group of lawmakers in Congress has introduced the Leadership in Critical and Emerging Technologies (“CET”) Act. The goal of the...more
A recent Patent Trial and Appeal Board decision related to hybrid quantum computing paves the way for more quantum computing-related patents, and potential litigation....more
After years of contemplation and delays, Europe’s Unified Patent Court will be operational in about one year. U.S.-based Life Sciences patent applicants should start preparing now to ensure that their applications withstand...more
2/10/2022
/ Biosimilars ,
Biotechnology ,
EU ,
Food & Drug Regulations ,
Generic Drugs ,
Intellectual Property Protection ,
Life Sciences ,
Patent Applications ,
Patents ,
Prescription Drugs ,
Unified Patent Court ,
Unitary Patent